Literature DB >> 2307626

Water soluble derivatives of rebeccamycin.

T Kaneko, H Wong, J Utzig, J Schurig, T Doyle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2307626     DOI： 10.7164/antibiotics.43.125

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


× No keyword cloud information.
  4 in total

1.  Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer.

Authors:  Anita Schwandt; Tarek Mekhail; Balazs Halmos; Timothy O'Brien; Patrick C Ma; Pingfu Fu; Percy Ivy; Afshin Dowlati
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

2.  A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors.

Authors:  Charles J Nock; Joanna M Brell; Joseph A Bokar; Matthew M Cooney; Brenda Cooper; Joseph Gibbons; Smitha Krishnamurthi; Sudhir Manda; Panayiotis Savvides; Scot C Remick; Percy Ivy; Afshin Dowlati
Journal:  Invest New Drugs       Date:  2009-09-23       Impact factor: 3.850

3.  A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer.

Authors:  Sanjay Goel; Scott Wadler; Anthony Hoffman; Fabio Volterra; Cheryl Baker; Elliot Nazario; Percy Ivy; Alyson Silverman; Sridhar Mani
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

4.  A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer.

Authors:  Maha Hussain; Ulka Vaishampayan; Lance K Heilbrun; Vikash Jain; Patricia M LoRusso; Percy Ivy; Lawrence Flaherty
Journal:  Invest New Drugs       Date:  2003-11       Impact factor: 3.850
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.